Eli Lilly and Company News - July 2026
Eli Lilly Retatrutide Succeeds in Phase 3, Showing 22.6% Weight Loss
Eli Lilly and Company reported positive topline results from its TRIUMPH-2 and TRIUMPH-3 Phase 3 trials for retatrutide. The investigational weight-loss drug...
Novo Nordisk sues Eli Lilly, alleging false ads for Zepbound and Mounjaro
Novo Nordisk filed a lawsuit in U.S. federal court against Eli Lilly for false and misleading advertising. The complaint targets marketing for Lilly’s...
Novo Nordisk wins EU approval for oral Wegovy, first GLP-1 pill
The European Commission approved Novo Nordisk’s once-daily oral version of Wegovy. This is the first oral GLP-1 treatment for weight management in the European...
🟢 LLY is trading 3.7% up today after Medicare pricing deal and Jaypirca label expansion
LLY is trading 3.7% up at $1244.16 following positive regulatory and reimbursement developments for its core drug portfolio. • An EMA panel recommended a...